Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1997-10-28
1999-08-17
Shah, Mukund J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
540572, A61K 3155, C07D24314
Patent
active
059394145
ABSTRACT:
Compounds having a benzodiazepine hydrazide core are described. These compounds are useful in the inhibition of HIV integrase, the prevention or treatment of infection by HIV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.
REFERENCES:
patent: 4102881 (1978-07-01), Tawada et al.
patent: 4820834 (1989-04-01), Evans et al.
Englund et al., Journal of Virology, vol. 69, No. 5, pp. 3216-3219, May 1995.
LaFemina et al. Journal of Virology, vol. 66, No. 12, pp. 7414-7419, Dec. 1992.
Cannon et al., Journal of Virology, vol. 68, No. 8, pp. 4768-4775, Aug. 1994.
Wiskerchen et al., Journal of Virology, vol. 69, No. 1, pp. 376-386 Jan. 1995.
La Femina et al., Antimicrobial Agents & Chemotherapy, vol. 39(2), pp. 320-324 (1995), "Inhibition of human immunodeficiency virus integrase by bis-catechols".
Cushman et al., J. Med. Chem., vol. 38 (1995), pp. 443-452. "Cosalane analogues with enhanced potencies as inhibitors of HIV-1 protease and integrase".
Mazumder et al., Biochemistry, vol. 34 (1995), pp. 15111-15122, "Effects of tyrphostins, protein kinase inhibitors, on human immunodeficiency virus type 1 integrase".
Mazumder et al., J. Med. Chem., vol. 39 (1996), pp. 2472-2481, "Antiretroviral agents as inhibitors of both human immunodeficiency virus type 1 integrase and protease".
Mazumder et al., Molecular Pharmacology, vol. 49 (1996), pp. 621-628, "Effects of nucleotide analogues on human immunodeficiency virus type 1 integrase".
Kusumoto et al., C.A. 120(19):238888s, "A comparative study on the inhibitory effects of flavonoids and alkaloids on reverse transcriptases of different retroviruses".
Mazumder et al., AIDS Research and Human Retroviruses, vol. 11(1), pp. 115-125 (1995), "Inhibition of human immunodeficiency virus type 1 integrase by a hydrophobic cation . . .".
Mazumder et al., Proc. Nat'l Acad. Sci. USA, vol. 91, pp. 5771-5775 (1994), "Inhibition of human immunodeficiency virus type 1 integrase by 3'-azido-3'-deoxythymidylate".
Steinbach et al., J. Org. Chem. 27 (1962), pp. 3788-3796, "Quinazolines and 1,4-benzodiazepines. VI Halo-, methyl-, and methoxy-substituted 1,3-dihydro-5-phenyl-2H-1, 4-benzodiazepin-2-ones".
Fesen et al., Proc. Nat'l Acad. Sci. USA, vol. 90 (1993), pp. 2399-2403, "Inhibitors of human immunodeficiency virus integrase".
Farnet et al., Proc. Nat'l Acad. Sci. USA, vol. 93 (1996), pp. 9742-9747, "Differential inhibition of HIV-1 preintegration complexes and purified integrase protein by small molecules".
Lutzke et al., Proc. Nat'l Acad. Sci. USA, vol. 92 (1995), pp. 11456-11460, "Identification of a hexapeptide inhibitor of the human immunodeficiency virus integrase protein by using a combinatorial chemical library".
Ojwang et al., Antimicrobial Agents & Chemotherapy, vol. 39(11), pp. 2426-2435(1995), "T30177, an oligonucleotide stabilized by an intramolecular guanosine octet, is a potent inhibitor . . .".
Eich et al., J. Med. Chem., vol. 39 (1996), pp. 86-95, "(-)-Arctigenin as a lead structure for inhibitors of human immunodeficiency virus type-1 integrase".
Vejdelek et al., Coll. Czech. Chem. Commun. 45(1980), pp. 3593-3616, "Psychotropic derivatives of 5-phenyl-7-chloro-1,3-dihydro-1,4-benzodiazepin-2-one and contribution to the synthesis of its 5-(2-chlorophenyl) analogue".
Vejdelek et al., Coll. Czech. Chem. Commun. 53 (1988), "Potential anxiolytics and hypnotics: 1-(alkanesulfonamidoalkyl)-6-aryl-8-halogeno-. . .".
Neamati et al., "Design and discovery of HIV-1 integrase inhibitors", DDT 2(11)(1997), pp. 487-498.
Hazuda et al., Nucleic Acids Research, vol. 22 (6), pp. 1121-1122(1994), "A novel assay for the DNA strand-transfer reaction of HIV-1 integrase".
Burke et al., J. Med. Chem., vol. 38 (1995), pp. 4171-4178, "Hydroxylated aromatic inhibitors of HIV-1 integrase".
Hazuda et al., J. of Virology, vol. 71(1), pp. 807-811 (1997), "Equivalent inhibition of half-site and full-site retroviral strand transfer reactions by structurally diverse compounds".
Fesen et al., Biochemical Pharma., vol. 48(3), pp. 595-608 (1994), "Inhibition of HIV-1 integrase by flavones, caffeic acid phenethyl ester (cape) and related compounds".
Carteau et al., Archives of Biochemistry & Biophysics, vol. 305(2), pp. 606-610 (1993), "Inhibitory effect of the polyanionic drug suramin on the in vitro HIV DNA integration reaction".
Robinson, Jr., et al., Proc. Nat'l Acad. Sci. USA, vol. 93 (1996), pp. 6326-6331, "Inhibitors of HIV-1 replication that inhibit HIV integrase".
PRNewswire, Sep. 17, 1996, "Aronex reports results for lead anti-HIV integrase inhibitor compound".
Bell Ian M.
Guare, Jr. James P.
Hazuda Daria Jean
Munson Peter M.
Thompson Wayne J.
Fitch Catherine D.
Kifle Bruck
Merck & Co. , Inc.
Shah Mukund J.
Winokur Melvin
LandOfFree
Benzodiazepine hydrazide derivatives as inhibitors of HIV integr does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Benzodiazepine hydrazide derivatives as inhibitors of HIV integr, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Benzodiazepine hydrazide derivatives as inhibitors of HIV integr will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-314954